

Human Resource Development of Clinicians and Laboratory Technologists for Blood Morphology Testing in Mongolia

● Background

In Mongolia, they have been attempting to execute the diagnosis and treatment of hematopoietic malignancies all in their own country. However, securing a human resource in this field has been a major issue. Also, medical staff in Mongolia had little opportunity to receive sufficient education in this field, both of which would be the reason why the number of the patients who are diagnosed with hematopoietic malignancies including leukemia has not been increased. Based on these backgrounds, the Japanese Society for Laboratory Hematology has been working on a training project related to hematopoietic disease diagnosis since 2019. In response to the request from the partner country, this project will be continued in this year, and we will develop a support project to further improve the technology of their country and to introduce Japanese advanced equipment and reagents.

● Outline

In this project, medical doctors and laboratory technologists being selected from the Mongolian External Quality Control Committee (MEQAS), **Mongolian association of health laboratorians** and the National First Hospital Hematology Department will receive our education through a visiting and on-line program. In addition, by collaborating with the responsible organizations in both countries, a manual on the diagnosis of hematopoietic diseases will be published in Mongolia, thereby widely improving the diagnostic ability in their country. In addition, in collaboration with hematology-related companies in Japan, we will provide technology for promoting the introduction of domestic equipment/reagents and appropriate equipment management.

● Outcome

We will train a total of 20 medical staffs who can carry out blood cell morphology examinations, so that institutions at which they belong become being able to execute diagnosis of hematopoietic malignancies. In addition, by preparing a guidebook they refer to, we will continuously improve their ability to diagnose hematopoietic diseases in their country.

